Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer

NCT06829823 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-muscle Invasive Bladder Cancer (NMIBC)

Interventions

DRUG: N-803 and BCG
DRUG: N-803 and Gemcitabine

Sponsor

ImmunityBio, Inc.